Toronto, ON (PRWEB) March 08, 2022 Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical
center for vaccine development at baylor college of medicine, we ve been developing low cost protein vaccines, the ones that the big pharma companies are not interested in. and then about a decade ago we began working on coronavirus vaccines, and now we ve been able to pivot that program around to covid-19 and developed a low-cost protein vaccine, same technology as used to make the hepatitis b vaccine which parents have been giving to their kids for the last 40 years, it s microbial fermentation and yeast. we licensed it without a patent, with no strings attached to biological e in india, and they re moving forward hopefully soon to release the vaccine for emergency use with an advanced purchase commitment of 300 million doses from the indian government. we ve also licensed them to indonesia, bangladesh, botswana. so, you know, if all the stars
'Animal-free’ protein startup The EVERY Company - which deploys synthetic biology to genetically engineer microbes to produce high-value ingredients such as egg proteins (without chickens) via precision fermentation - has closed a $175m series C round co-led by McWin and Rage Capital.
Shiru - an Emeryville, CA-based startup producing proteins via microbial fermentation to create label-friendly alternatives to everything from methylcellulose to gelatin and casein - has closed a $17m Series A round led by S2G Ventures that will help it launch a pilot scale facility in early 2022.